Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 2.14 USD 7.54%
Market Cap: 208.9m USD

During the last 3 months Editas Medicine Inc insiders have not bought any shares, and sold 14.6k USD worth of shares. The stock price has dropped by 46% over this period (open performance analysis).

The last transaction was made on Dec 3, 2025 by Burkly Linda , who sold 1.5k USD worth of EDIT shares.

Last Transactions:
Burkly Linda
$-1.5k
Parison Amy
$-992.6
O'neill Gilmore Neil
$-12.1k
Burkly Linda
$-1.8k
Parison Amy
$-1.2k
O'neill Gilmore Neil
$-14.5k
Parison Amy
$-1.8k
Burkly Linda
$-12.8k
Burkly Linda
$-1.3k
Parison Amy
$-768.9
O'neill Gilmore Neil
$-26.2k
Lucera Erick
$-7k
O'neill Gilmore Neil
$-28.5k
Burkly Linda
$-4.9k
O'neill Gilmore Neil
$-3.4k
Mei Baisong
$-1.1k
O'neill Gilmore Neil
$-5.3k
Mei Baisong
$-1.8k
Burkly Linda
$-64.4k
Mei Baisong
$-34.5k
Mei Baisong
$-2.8k
O'neill Gilmore Neil
$-67k
Lucera Erick
$-125.4k
Hopfield Jessica
$+253.9k
O'neill Gilmore Neil
$-732.9k
Mei Baisong
$-191.4k
Eaton Bruce
$-1.1k
Eaton Bruce
$-5.7k
Eaton Bruce
$-1.2k
Eaton Bruce
$-908.5
Eaton Bruce
$-6k
Eaton Bruce
$-1.2k
View All Transactions

During the last 3 months Editas Medicine Inc insiders have not bought any shares, and sold 14.6k USD worth of shares. The stock price has dropped by 46% over this period (open performance analysis).

The last transaction was made on Dec 3, 2025 by Burkly Linda , who sold 1.5k USD worth of EDIT shares.

Sold
0-3
months
14.6k USD
3
3-6
months
32.1k USD
3
6-9
months
28.2k USD
3
9-12
months
40.4k USD
3
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Editas Medicine Inc
Insider Trading Chart

Editas Medicine Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Editas Medicine Inc
Last Insider Transactions

Global
Insiders Monitor

Editas Medicine Inc
Glance View

Market Cap
199.6m USD
Industry
Biotechnology

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.

EDIT Intrinsic Value
0.69 USD
Overvaluation 68%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top